|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Motor_Neurone_Disease
|
|
gptkbp:activities
|
glutamate release inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Rilutek
|
|
gptkbp:class
|
neuroprotective agent
|
|
gptkbp:clinical_trial
|
Phase II
slow disease progression
Phase III
Phase I
prolong survival
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
pharmaceutical synthesis
organic synthesis
|
|
gptkbp:contraindication
|
liver disease
pregnancy
breastfeeding
hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Sanofi
|
|
gptkbp:dosage_form
|
gptkb:software_framework
gptkb:tablet
|
|
gptkbp:effective_date
|
gptkb:1995
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Riluzole
|
|
gptkbp:ingredients
|
C10 H10 N2 O3 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
antidepressants
anticonvulsants
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_atype_of
|
N07 X X02
|
|
gptkbp:is_used_for
|
gptkb:amyotrophic_lateral_sclerosis
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
gptkb:ALS
gptkb:psychologist
motor neuron disease
glutamate toxicity
|
|
gptkbp:safety_features
|
Category C
not recommended during pregnancy
monitor liver function
monitor for side effects
use with caution in elderly
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
liver enzyme elevation
|
|
gptkbp:type_of
|
175481-16-0
|